EG385328 Inhibitors
EG385328 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of a molecular entity identified as EG385328. These inhibitors are structurally diverse, often featuring various substituent groups and molecular frameworks that allow them to bind to their target with high affinity. The binding typically occurs through non-covalent interactions, such as hydrogen bonding, hydrophobic effects, or van der Waals forces, which contribute to the specificity and potency of these inhibitors. The chemical backbones of EG385328 inhibitors often include heterocyclic ring systems, aromatic moieties, and other functional groups that enhance their stability, solubility, and ability to interact effectively with the target molecule. The design of these inhibitors is based on understanding the molecular structure and binding pockets of EG385328, enabling the development of compounds with optimized binding characteristics and minimal off-target effects.
These inhibitors are typically characterized by their ability to block the enzymatic or binding activity of EG385328, leading to alterations in downstream molecular pathways. The efficacy of these inhibitors is often measured in terms of their binding affinity, specificity for EG385328 over other potential targets, and stability under various physiological conditions. The pharmacokinetic and physicochemical properties of these compounds, such as their solubility, bioavailability, and potential to cross biological membranes, are critical for their overall activity and utility in research. Additionally, modifications to the core structure of these inhibitors allow for fine-tuning of their selectivity and potency, enabling researchers to develop both reversible and irreversible inhibitors based on the desired mechanism of action. Understanding the interactions between EG385328 and its inhibitors has implications for studying biochemical pathways and elucidating the function of EG385328 in different biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor impacting histone acetylation. Trichostatin A directly inhibits H2al1n by promoting histone hyperacetylation, potentially disrupting chromatin structure and influencing heterochromatin assembly. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor. 5-Azacytidine directly inhibits H2al1n by reducing DNA methylation, potentially altering chromatin configuration and impacting the process of heterochromatin assembly. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor. JQ1 directly inhibits H2al1n by targeting bromodomain-containing proteins, potentially disrupting chromatin structure and influencing the assembly of heterochromatin. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
PARP inhibitor. A-485 indirectly inhibits H2al1n by impacting the PARylation process, potentially affecting chromatin structure and the dynamics of heterochromatin assembly. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
EZH2 inhibitor. GSK343 directly inhibits H2al1n by targeting the histone methyltransferase EZH2, potentially modulating chromatin structure and influencing heterochromatin assembly through alterations in histone methylation. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
DNA methyltransferase inhibitor. RG108 directly inhibits H2al1n by reducing DNA methylation, potentially altering chromatin configuration and impacting the process of heterochromatin assembly. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EZH2 inhibitor. EPZ-6438 directly inhibits H2al1n by targeting the histone methyltransferase EZH2, potentially modulating chromatin structure and influencing heterochromatin assembly through alterations in histone methylation. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
G9a/GLP histone methyltransferase inhibitor. BIX-01294 directly inhibits H2al1n by targeting G9a/GLP, potentially impacting chromatin structure and the assembly of heterochromatin through alterations in histone methylation. | ||||||
Scriptaid | 287383-59-9 | sc-202807 sc-202807A | 1 mg 5 mg | $64.00 $183.00 | 11 | |
HDAC inhibitor impacting histone acetylation. Scriptaid directly inhibits H2al1n by promoting histone hyperacetylation, potentially disrupting chromatin structure and influencing heterochromatin assembly. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
G9a/GLP histone methyltransferase inhibitor. UNC0638 directly inhibits H2al1n by targeting G9a/GLP, potentially impacting chromatin structure and the assembly of heterochromatin through alterations in histone methylation. | ||||||